

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

SMN

RRID:AB_397973

Type: Antibody

Proper Citation

BD Biosciences Cat# 610647, RRID:AB_397973

Antibody Information

URL: http://antibodyregistry.org/AB_397973

Proper Citation: BD Biosciences Cat# 610647, RRID:AB_397973

Target Antigen: SMN

Host Organism: mouse

Clonality: monoclonal

Comments: Immunofluorescence

Antibody Name: SMN

Description: This monoclonal targets SMN

Target Organism: rat, canine, mouse, dog, human

Defining Citation: [PMID:16786553](#)

Antibody ID: AB_397973

Vendor: BD Biosciences

Catalog Number: 610647

Record Creation Time: 20250820T002303+0000

Record Last Update: 20250820T080739+0000

Ratings and Alerts

No rating or validation information has been found for SMN.

No alerts have been found for SMN.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zobaroğlu Özer P, et al. (2026) Modulating microtubule stability via α -tubulin acetylation partially restores Golgi fragmentation in spinal muscular atrophy. Turkish journal of biology = Turk biyoloji dergisi, 50(2), 158.

Huang WP, et al. (2025) M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development. Science advances, 11(30), eadx1357.

Pagiazitis JG, et al. (2025) Catecholaminergic dysfunction drives postural and locomotor deficits in a mouse model of spinal muscular atrophy. Cell reports, 44(1), 115147.

Xiang T, et al. (2025) Loss of SMN Impairs Osteoblast-Osteoclast Coupling via IGF1-Akt-OPG Axis in Spinal Muscular Atrophy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(20), e71095.

Hodgson RE, et al. (2024) C9orf72 poly-PR forms anisotropic condensates causative of nuclear TDP-43 pathology. iScience, 27(10), 110937.

Wang L, et al. (2024) Arginine methylation-enabled FUS phase separation with SMN contributes to neuronal granule formation. Cell reports, 43(8), 114537.

Hann SH, et al. (2024) Depletion of SMN protein in mesenchymal progenitors impairs the development of bone and neuromuscular junction in spinal muscular atrophy. eLife, 12.

Muiños-Bühl A, et al. (2023) Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects. International journal of molecular sciences, 24(4).

Oiwa K, et al. (2023) Monomerization of TDP-43 is a key determinant for inducing TDP-43 pathology in amyotrophic lateral sclerosis. Science advances, 9(31), eadf6895.

Kim JK, et al. (2023) A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses. Neuron, 111(9), 1423.

Ikenaka A, et al. (2023) SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis. Life science alliance, 6(3).

Tisdale S, et al. (2022) SMN controls neuromuscular junction integrity through U7 snRNP. Cell reports, 40(12), 111393.

Ravel-Chapuis A, et al. (2022) A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophy. *Human molecular genetics*, 31(9), 1453.

Marasco LE, et al. (2022) Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. *Cell*, 185(12), 2057.

Du LL, et al. (2022) NOVA1 promotes SMN2 exon 7 splicing by binding the UCAC motif and increases SMN protein expression. *Neural regeneration research*, 17(11), 2530.

Muinos-Bühl A, et al. (2022) Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks. *Neurobiology of disease*, 171, 105795.

Quinodoz SA, et al. (2021) RNA promotes the formation of spatial compartments in the nucleus. *Cell*, 184(23), 5775.

McCormack NM, et al. (2021) A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein. *Cell reports*, 35(6), 109125.

Buettner JM, et al. (2021) Central synaptopathy is the most conserved feature of motor circuit pathology across spinal muscular atrophy mouse models. *iScience*, 24(11), 103376.

Pagliarini V, et al. (2020) Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. *Journal of neurochemistry*, 153(2), 264.